Lacosamid Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilizes hyperexcitable neurons, limits repetitive firing, and thereby reduces the spread of epileptiform activity without significantly affecting normal neuronal conduction.

The dosage of Lacosamid Fresenius Kabi is determined by the prescribing clinician based on the patient’s clinical condition, age, renal and hepatic function, and response to therapy. The prescriber will set the appropriate dose and infusion rate.

Safety data for lacosamide in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with a healthcare professional is essential before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents, and may have a distinct side‑effect profile, particularly regarding cardiac conduction.

Lacosamid Fresenius Kabi should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability.

The product is supplied as an intravenous solution and is administered by slow infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are set according to the prescriber’s instructions.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation and atrioventricular block, as well as rare severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for these events, especially if they have pre‑existing cardiac conditions.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid use. Additionally, individuals with significant cardiac conduction disorders, such as existing PR‑interval prolongation, should not receive the drug without careful cardiac monitoring.